"R ehabilitation pharmacology" experiments in animals suggest that poststroke recovery may be enhanced by combining rehabilitative training with dextroamphetamine (AMPH), possibly because of increased noradrenergic neurotransmission and facilitation of activity-dependent neuroplasticity. [1] [2] [3] [4] Maximum improvement occurs when drug administration is coupled with task-specific practice. 2, 5 A dose-response effect has been identified, 6 and multiple doses on an intermittent basis appear most effective. 3 Specificity has been shown for the noradrenergic agonists, implicating norepinephrine as a neurochemical mediator of recovery; drugs decreasing noradrenergic activity impair recovery and can reinstate deficits after recovery. 1, 2, 4 Biologic plausibility has been established by studies showing that AMPH induces physiological or structural changes in the brain that may be relevant to recovery. In rats, AMPH upregulates neural sprouting and synaptogenesis in peri-infarct cortex and contralateral cortex. 7 At the synaptic level, AMPH and other noradrenergic agonists facilitate long-term potentiation, the cellular model of learning and memory. 8 In humans, 10 mg AMPH facilitates the effects of motor training on usedependent plasticity as measured by transcranial magnetic stimulation, 9 suggesting that this dose is sufficient for producing a measurable neurophysiological effect in humans.
Small pilot trials have demonstrated safety, feasibility, and proof-of-concept for the use of AMPH in poststroke motor rehabilitation for carefully selected patients, but clinical efficacy remains uncertain. 10 -20 A statistically significant small magnitude enhancement of aphasia recovery has been demonstrated when AMPH is paired with speech-language therapy. 21 Despite the limited data, some rehabilitation centers already prescribe AMPH or similar agents as part of clinical routine. It is unclear which patients, if any, may benefit from such intervention. This study aimed to investigate more definitively the efficacy of AMPH-coupled physiotherapy on recovery from hemiparesis, as measured by validated scales of motor impairment and disability at standardized times after stroke.
Methods

Study Participants
We studied patients with acute unilateral cerebral hemispheric stroke causing hemiplegia or hemiparesis. Hemiparesis severity was rated on days 5 to 10 after stroke on the Fugl-Meyer (FM) motor scale 22 as severe (0 -35) or moderate (36 -79); patients with mild hemiparesis (80 -100) were not included. Patients were included if they were medically fit to participate in a rehabilitation program, had no significant premorbid disability, and provided informed consent. Exclusions included brain stem/cerebellar stroke; pre-existing deficit that could interfere with assessments; dementia; unstable angina, congestive heart failure, unstable arrhythmia, or uncontrolled hypertension; psychosis; and use of ␣-adrenergic antagonists/agonists or monoamine oxidase inhibitors.
Design and Setting
We used a randomized, double-blind, placebo-controlled, repeatedmeasures design. Participants were recruited from 5 acute care hospitals (Toronto, Canada; January 2000 to April 2003). Randomization was stratified by hospital and severity of motor deficit. A blocked randomization sequence was used. Study treatments began in hospital and continued on transfer to 1 of 6 participating local inpatient rehabilitation centers. Research ethics board approval was obtained at each site. All participants, investigators, study physiotherapist, and treating clinicians were blinded to each patient's treatment status.
Drug Intervention
A total of 10 mg of AMPH sulfate (Dexedrine) or identical placebo capsules was administered as a single oral dose followed 90 minutes later by a 1-hour physiotherapy session to coincide with the timing of peak pharmacological action of AMPH. The first treatment began 5 to 10 days after stroke. This time frame was chosen: (1) to initiate rehabilitation early (during the period of maximum recovery and neuroplasticity); (2) to allow time for patients to stabilize medically before enrollment; and (3) to permit exclusion of patients who were rapidly improving during the first week, and thus achieve a more homogenous sample of patients with persisting moderate-severe hemiparesis. Treatments continued every third or fourth day for a total of 10 drug therapy sessions (ie, every Monday/Thursday or every Tuesday/Friday for 5 weeks). Drug administration was verified at the time of each scheduled dose, and any protocol deviations were documented.
Physiotherapy Intervention
One physiotherapist provided the study treatments for all participants. Treatment was based on neurodevelopmental principles of remediation with the goal of facilitating return of normal movements and inhibiting abnormal movement patterns. Sessions were individualized based on patient abilities, "hands-on," goal-oriented, and required active participation. Movements were practiced within progressively more complex functional activities to facilitate return of selective muscle control of trunk and limbs (eg, progression from independent midline sitting with trunk control to transitional movements [reach, sit-to-stand], to standing with symmetrical weightbearing, to stepping with controlled weight shift and walking). Treatment of the limbs progressed from recruiting muscle activity for stabilization in support or weight-bearing to controlled, coordinated, selective movements for function and manipulation. Patients were challenged to work at a level just above their ability, and assistance with the missing components of normal movement was provided. All participants continued to receive standard care (organized inpatient stroke team care and multidisciplinary rehabilitation) that is provided free of charge to all residents of Ontario, and the amount of physiotherapy provided as part of standard care was documented for each patient.
Outcome Measures
The primary outcome measure was the FM motor scale, a strokespecific impairment index that is widely used for assessment of motor recovery. 22, 23 Excellent intrarater and inter-rater reliability and validity have been demonstrated. 23, 24 The motor domain ranges from 0 (flaccid hemiplegia) to 100 (normal movement), with 66 points for the upper extremity and 34 points for the lower extremity. Each item is scored on a 3-point ordinal scale (0 cannot perform, 1 performs partially, and 2 performs fully). All motor assessments were performed by 1 physiotherapist at 13 standardized times: baseline (within 24 hours of the first study treatment), at each of the 10 treatment sessions, 3 to 4 days after the final treatment (Ϸ6 weeks after stroke), and 3 months. All secondary outcomes were measured by 1 physiotherapist: Functional Independence Measure, 25 ChedokeMcMaster Disability Inventory to assess general mobility, 26 Clinical Outcome Variable Scale (COVS) to quantify ambulation, 27 and Chedoke-McMaster Arm and Hand Activity Inventory to assess upper limb function. 28 The study coordinator monitored for drug toxicity by patient/caregiver interview and hospital chart review. A checklist was used to identify symptoms of psychomotor stimulation. All adverse events and prescription medications were documented.
Statistical Analysis
Baseline characteristics were analyzed using descriptive statistics and compared using Student's t test or 2 test. The efficacy of AMPH versus placebo was assessed over 13 time points (baseline to 3 months) in a 2ϫ13 repeated-measures ANOVA for scores on the FM scale. Prespecified analyses assessed recovery in separate models for the moderate and severe subgroups and for patients with cortical stroke. For the secondary outcomes, the 2 groups were compared at baseline, 6 weeks, and 3 months in a 2ϫ3 repeated-measures ANOVA.
Results
Patient Characteristics
Of 71 patients enrolled, 67 completed the study treatments and were included in the analysis. Follow-up was complete at 6 weeks; at 3 months, 66 patients were alive and all had complete follow-up ( Figure 1 ). Mean age was 68 years, and the majority were living at home and independent before admission ( Table  1) . Two patients were enrolled with a presumed internal capsule lacunar stroke, but repeat imaging revealed a brain stem infarct. At baseline, hemiparesis was severe overall (mean FM motor Results expressed as meanϮSD, unless specified otherwise.
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score 27.7Ϯ20.0), all had a modified Rankin scale score Ն3, and 88.0% had no functional ambulation. The 2 groups were well balanced in terms of baseline demographic characteristics and stroke severity in the entire cohort (nϭ67) and in the severe hemiparesis subgroup (nϭ43). In the moderate hemiparesis subgroup (nϭ24), there was a significant imbalance in baseline FM scores in the AMPH group versus placebo: total motor scores 46.6Ϯ10.6 versus 57.9Ϯ7. 5 
Treatment
Study treatments began on poststroke day 8.1Ϯ1.9 for the AMPH group and 8.6Ϯ1.5 for the placebo group (Pϭ0.33). There were no differences between the groups in the proportion of patients treated at each of the acute care hospitals (Pϭ0.88) or rehabilitation hospitals (Pϭ0.47). Patients who did not receive inpatient rehabilitation (3 AMPH; 3 placebo) received the remainder of their study treatments at home. The 2 groups did not differ in the total amount of physiotherapy (minutes) received during the intervention period, either as part of the study (582.7Ϯ48.6 versus 566.4Ϯ63.6; Pϭ0.25) or as part of standard care (684.0Ϯ265.9 versus 636.4Ϯ347.8; Pϭ0.58). Four patients (0 AMPH; 4 placebo) received tissue plasminogen activator. Twenty-three patients were exposed to Ն1 doses of the following medications during the intervention period: benzodiazepine (7 AMPH; 6 placebo), neuroleptic (0 AMPH; 1 placebo), selective serotonin reuptake inhibitor (6 AMPH; 9 placebo), and methylphenidate (0 AMPH; 1 placebo). Excluding these patients from the primary analysis did not affect the results. No patients received phenytoin or phenobarbital, and AMPH was not prescribed outside of the trial for any patient.
Safety and Tolerability
The study drug was well tolerated and no patient had to discontinue treatment (Table 2 ). There were virtually no observable psychostimulant effects of AMPH, which prevented the study physiotherapist from having any indication of group assignment. The success of blinding was assessed by comparing the physiotherapist's predicted versus actual drug assignments for each patient, which were no greater than chance (49% agreement). Only 1 patient had a symptom that was probably related to AMPH (visual hallucinations after the first dose).
Recovery in the Entire Cohort
Motor scores and independence in activities of daily living improved during treatment in both groups (Table 3) . Mean improvement on the FM motor scale was 24.7Ϯ15.5 during the intervention (baseline to 6 weeks) and 4.5Ϯ6.0 after the intervention (6 weeks to 3 months). At 3 months, nearly one third had recovered to a mild hemiparesis (FM motor score 80 to 100); mean Functional Independence Measure score 105.8Ϯ20.6; and three quarters regained independent ambulation (Clinical Outcome Variable Scale score Ն4).
Efficacy
Repeated-measures ANOVA over the 13 time points revealed no significant differences (main or interaction effects) between the AMPH and placebo groups on the primary outcome of recovery on the FM motor scale for the entire cohort (Fϭ0.88; Pϭ0.35) or in separate models for the severe (Fϭ0.02; Pϭ0.90) or moderate (Fϭ2.99, Pϭ0.10) subgroups (Figure 2 ). Separate models for upper extremity and lower extremity motor scores revealed no significant main effects in the entire cohort or in the severe subgroup.
In the moderate hemiparesis subgroup, there was a significant main effect of AMPH on upper extremity motor recovery (between-group difference 11.6 points; 95% CI, 4.6 to 18.5; Fϭ11.88; Pϭ0.002) with a significant drugϫtime interaction (Fϭ5.14; PϽ0.001; Figure 2) .
A separate analysis for the subgroup of patients with only cortical or mixed cortical/subcortical stroke (ie, pure subcortical and brain stem strokes excluded) revealed no significant between-group difference in motor recovery (Fϭ0.01; Pϭ0.92).
There were no significant between-group differences on any of the secondary outcome measures. At 3 months, there was no difference between the groups in the proportion of patients discharged home, remaining in inpatient rehabilitation, or admitted to a nursing home/retirement home for the entire cohort (Pϭ0.56) or the severe (Pϭ0.60) or moderate (Pϭ0.73) subgroups. After inpatient rehabilitation, 82.8% of AMPH-treated patients and 85.3% of placebo-treated patients returned home (Pϭ0.96).
Discussion
To our knowledge, this is the largest published trial investigating amphetamine-coupled stroke rehabilitation. The addition of AMPH 10 mg to physiotherapy was safe and well tolerated but provided no benefit on total motor scores or disability measures compared with physiotherapy alone when given for 10 doses over 5 weeks. Both groups improved during the treatment period, then plateaued after the intervention, suggesting a possible benefit of the additional physiotherapy provided in this study. Our trial design, modeled after Walker-Batson et al, 12 used an intermittent dosing protocol and tight coupling of AMPH with rehabilitative training to parallel the design of animal studies demonstrating AMPHfacilitated recovery. 3 Our study extends previous trials by inclusion of patients with moderate in addition to severe motor deficits, separation of cortical from pure subcortical strokes, and analysis of repeated-measures data collected over multiple time points during the intervention period. Follow-up was complete, and our sample size was sufficient to detect a Ն15-point difference in improvement between the groups if such a difference existed. We minimized variability in the rehabilitation intervention because all study treatments were administered by 1 physiotherapist, and we minimized regional differences in rehabilitation practices because this was a singlecity study. Inter-rater variability was eliminated because all primary and secondary outcomes were rated by 1 examiner.
Previous studies of AMPH in poststroke motor rehabilitation have been limited by small sample sizes (8 to 45 patients) and differing methodologies. Most have focused exclusively on patients with severe hemiparesis or have not reported outcomes in moderate patients. Three published trials investigated AMPH coupled with physiotherapy using a similar 5-week intermittent dosing schedule, with the timing of outcome assessments identical to our study. The study by Walker-Batson et al has been cited widely for suggesting efficacy of AMPH; 12 however, with only 10 subjects, the observed benefit of AMPH could have resulted from random chance and the poor recovery in their placebo group (mean change only 11 points from baseline to end of treatment). Sonde et al used an identical trial design to our study and also found no benefit in 36 patients on the FM motor scale or Barthel Index, although 10 mg of d,l-amphetamine instead of d-amphetamine was used. 18 Treig et al studied 24 patients in a nearly identical design and found no significant difference between AMPH and placebo on the Rivermead Motor Assessment or Barthel Index. 19 Together, these 2 studies and our present data, although confirming the safety and feasibility of AMPH in stroke rehabilitation, do not demonstrate enhancement in motor recovery with this dosing regimen and treatment schedule.
We observed a greater rate of upper limb motor recovery for patients with a moderate severity hemiparesis. However, interpretation of this result is complicated by the fact that randomization failed to produce treatment groups that were balanced in terms of baseline motor scores in the moderate subgroup: baseline upper extremity motor scores were significantly worse in the AMPH group versus placebo (mean difference 17.9 points; PϽ0.001), yet by 6 weeks, the 2 groups had improved to almost the same level. The lower initial motor scores could have favored the AMPH group because of regression to the mean; indeed, natural history studies show that the recovery rate during the first 6 weeks is greater for patients with initially more severe hemiparesis compared with those with moderate or mild hemiparesis. 24 Furthermore, the ceiling effect of the scale limits its ability to measure change in milder stroke patients, 23 and this may explain why the placebo group did not appear to improve as much relative to the AMPH group. Therefore, any apparent benefit of AMPH in accelerating motor recovery in this subgroup should be considered hypothesis-generating only. Similarities in the design of our study with other studies could facilitate meta-analysis to address this hypothesis.
Limitations of this study reflect challenges inherent in the design of any stroke rehabilitation trial. 29 We experienced similar difficulty with patient recruitment that other studies have faced (Ϸ40 patients screened for every 1 enrolled) because of strict entry criteria. Although we chose a highly select group of stroke patients, there remained substantial within-subject variability in recovery because of the wide heterogeneity in stroke type, lesion size, lesion location, accompanying deficits, comorbidities, and other unmeasured factors. Such variability in individual recovery has plagued many rehabilitation studies because small treatment effects are difficult to detect. The physiotherapy intervention was standardized as much as possible, but inevitably, therapy sessions depended on individual patient abilities, treatment time was divided between the upper and lower extremities, and it was not possible to control the content or intensity of other rehabilitation services provided outside of the trial as part of standard care.
This study has implications for research and clinical practice. First, our data do not support the routine use of AMPH as a treatment outside of a clinical trial. Second, this study reinforces the complexities of extrapolating results from animal (mostly rodent) models to human trials and forces us to rethink the design of future studies. 29 Clinical efficacy of AMPH-coupled rehabilitation may require higher drug doses, more frequent and longer duration treatments, a more focused and standardized rehabilitation intervention, and improved patient selection. Based on our subgroup analysis, further studies should target patients with moderate paresis; this is consistent with other trials showing that patients with moderate paresis are more responsive to additional training than those with severe motor deficits. 30 Theoretically, patients with small cortical strokes should be the best candidates for AMPH, and future trials should stratify patients by lesion characteristics. The 10-mg dose is likely too low, given that in rats and cats, the optimal dose is Ͼ1 mg/kg. 6 Dose-limiting toxicity has been a reason that other investigational stroke treatments have failed in clinical trials after appearing successful in animals. Recently, 20 mg per day of AMPH has been shown to be safe in stroke patients, although it is associated with small increases in blood pressure and heart rate. 14 Moreover, the "dosage" of physiotherapy is likely a critical factor: many more additional hours of therapy are probably necessary to produce measurable benefit. 31 Ideally, the chosen therapy should be one that has demonstrated efficacy, is reproducible and can be standardized among trial participants, and is specifically focused on either the upper limb or lower limb/gait. Further insights from experiments in nonhuman primates and ongoing clinical studies are eagerly awaited and may allow more rational clinical trial design.
